Table 1.
Overview of the frequency of TERT promoter mutations in soft tissue and bone sarcomas reported in the literature: Number of mutated cases/total cases (mutation rate, in percentage).
| Present Study (n = 116) 22 Subtypes |
Saito 2016 (n = 180) 19 Subtypes |
Campanella 2016 (n = 68) 15 Subtypes |
Koelsche 2014 (n = 341) 16 Subtypes |
Killela 2013 (n = 95) 6 Subtypes |
|
|---|---|---|---|---|---|
| Soft tissue sarcomas | |||||
| WDLS | 0/5 (0%) | 0/18 (0%) | 0/1 (0%) | NA | NA |
| Myxoid liposarcoma | 4/9 (44%) | 3/13 (23%) | 2/9 (22.2%) | 29/39 (74%) | 19/24 (79.1%) |
| Pleomorphic liposarcoma | 1/4 (25%) | NA | 1/1 (100%) | 0/15 (0%) | NA |
| Dedifferentiated liposarcoma | 0/12 (0%) | NA | 1/1 (100%) | 0/61 (0%) | NA |
| Liposarcoma | 0/7 (0%) | NA | NA | NA | NA |
| Leiomyosarcoma | 0/9 (0%) | 0/24 (0%) | 0/13 (0%) | 0/27 (0%) | NA |
| Cytosarcoma Phyllodes | 0/1 (0%) | NA | NA | NA | NA |
| Angiosarcoma | 0/3 (0%) | NA | NA | 0/9 (0%) | NA |
| Rabdomyosarcoma | 0/8 (0%) | 0/5 (0%) | NA | NA | NA |
| Haemangiosarcoma | 0/1 (0%) | NA | NA | NA | NA |
| MPNST | 0/8 (0%) | 0/1 (0%) | 0/7 (0%) | 2/35 (6%) | NA |
| UPS (previous MFH) | 2/9 (22.2%) | 1/22 (4.5%) | 0/12 (0%) | 0/40 (0%) | NA |
| Fibrosarcoma | NA | NA | 0/1 (0%) | NA | 1/3 (33.3%) |
| Myofibroblastic sarcoma | 0/3 (0%) | NA | 0/3 (0%) | NA | NA |
| Myxofibrosarcoma | 0/1 (0%) | 0/6 (0%) | 0/5 (0%) | 0/17 (0%) | 1/10 (10%) |
| NOS | 0/11 (0%) | NA | NA | NA | NA |
| NOS, poorly differentiated | 1/8 (12.5%) | NA | NA | NA | NA |
| Clear cell sarcoma | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 0/5 (0%) | NA |
| Synovial sarcoma | 0/9 (0%) | 0/7 (0%) | 0/9 (0%) | 1/25 (4%) | NA |
| Ewing sarcoma | 0/1 (0%) | 0/6 (0%) | NA | NA | NA |
| SFT | 1/1 (100%) | 5/40 (12.5%) | 0/1 (0%) | 4/31 (13%) | 2/10 (20%) |
| Bone sarcomas | |||||
| Chondrosarcoma | 2/8 (25%) | 0/10 (0%) | NA | 0/8 (0%) | 1/2 (50%) |
| Osteosarcoma | 0/3 (0%) | 0/14 (0%) | NA | NA | 1/23 (4.3%) |
| Overall | 11/116 (9.5%) | 9/167 (5.4%) | 4/68 (5.9%) | 36/341 (10.5%) | 25/72 (34.7%) |
NA—not available; WDS—well-differentiated liposarcoma; UPS—undifferentiated pleomorphic sarcoma; MPNST—malignant peripheral nerve sheath tumor; SFT—solitary fibrous tumor; MFH—malignant fibrous histiocytoma; NOS—not otherwise specified; UPS—undifferentiated pleomorphic sarcoma.